Bamco Inc. NY Invests $1.18 Million in Kymera Therapeutics, Inc. (NASDAQ:KYMR)

Bamco Inc. NY purchased a new position in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 25,000 shares of the company's stock, valued at approximately $1,183,000.

Other hedge funds have also recently added to or reduced their stakes in the company. Massachusetts Financial Services Co. MA increased its position in Kymera Therapeutics by 11.7% during the third quarter. Massachusetts Financial Services Co. MA now owns 453,377 shares of the company's stock worth $21,458,000 after purchasing an additional 47,507 shares during the last quarter. Bank of New York Mellon Corp boosted its stake in shares of Kymera Therapeutics by 19.3% in the second quarter. Bank of New York Mellon Corp now owns 156,211 shares of the company's stock valued at $4,663,000 after purchasing an additional 25,317 shares during the period. Renaissance Technologies LLC purchased a new position in Kymera Therapeutics in the second quarter worth approximately $4,271,000. Eventide Asset Management LLC lifted its stake in Kymera Therapeutics by 9.9% in the third quarter. Eventide Asset Management LLC now owns 507,902 shares of the company's stock worth $24,039,000 after acquiring an additional 45,803 shares during the last quarter. Finally, E Fund Management Co. Ltd. lifted its stake in Kymera Therapeutics by 391.2% in the second quarter. E Fund Management Co. Ltd. now owns 48,946 shares of the company's stock worth $1,461,000 after acquiring an additional 38,981 shares during the last quarter.

Insider Buying and Selling

In other news, Director Pamela Esposito sold 13,500 shares of Kymera Therapeutics stock in a transaction that occurred on Tuesday, September 17th. The shares were sold at an average price of $48.28, for a total transaction of $651,780.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Corporate insiders own 15.82% of the company's stock.

Kymera Therapeutics Trading Down 1.9 %

Shares of NASDAQ KYMR traded down $0.89 on Wednesday, reaching $46.02. 373,524 shares of the company traded hands, compared to its average volume of 583,955. Kymera Therapeutics, Inc. has a fifty-two week low of $20.46 and a fifty-two week high of $53.27. The company has a 50 day moving average of $46.55 and a 200 day moving average of $42.45. The stock has a market capitalization of $2.98 billion, a PE ratio of -19.67 and a beta of 2.16.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last posted its earnings results on Thursday, October 31st. The company reported ($0.82) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.83) by $0.01. The firm had revenue of $3.74 million during the quarter, compared to the consensus estimate of $10.34 million. Kymera Therapeutics had a negative net margin of 191.26% and a negative return on equity of 24.96%. The company's revenue was down 20.9% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.90) EPS. As a group, research analysts expect that Kymera Therapeutics, Inc. will post -2.79 earnings per share for the current year.

Analysts Set New Price Targets

KYMR has been the subject of several recent analyst reports. Wells Fargo & Company upgraded shares of Kymera Therapeutics from an "equal weight" rating to an "overweight" rating and boosted their price objective for the stock from $38.00 to $57.00 in a research report on Monday. Leerink Partnrs raised shares of Kymera Therapeutics to a "strong-buy" rating in a research note on Monday, September 9th. Wolfe Research raised shares of Kymera Therapeutics from a "peer perform" rating to an "outperform" rating and set a $65.00 price target on the stock in a research note on Monday, August 26th. Leerink Partners reiterated an "outperform" rating and issued a $60.00 price objective on shares of Kymera Therapeutics in a research report on Monday, September 9th. Finally, Truist Financial reiterated a "buy" rating and issued a $53.00 price objective (down from $54.00) on shares of Kymera Therapeutics in a research report on Friday, November 1st. Three investment analysts have rated the stock with a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $53.40.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.